Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US01438T1060
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG0029H8ZF6
ALDX
Aldeyra Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Aldeyra Therapeutics Inc
ISIN
US01438T1060
TICKER
ALDX
MIC
XNAS
REUTERS
ALDX.OQ
BLOOMBERG
ALDX US
Mo., 27.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securities...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 26.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 24.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securities...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Aldeyra Therapeutics
US01438T1060

Key Dates and Disclosure Events Shareholders Need to KnowNEW YORK, April 23, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) to contact the firm. WHO IS AFFECTED: Those who purchased ALDX securities between November 3, 2023 and March 16, 2026 may be entitled to recover damages. F...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Aldeyra Therapeutics
US01438T1060

If you have suffered a loss on your Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have u...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securi...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Aldeyra Therapeutics
US01438T1060

Executive Accountability: Michael Alferi Named in Securities ActionNEW YORK, April 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors that Michael Alferi, Head of Finance, principal financial officer, and principal accounting officer of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), is named as an individual defendant in a securitie...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securi...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Aldeyra Therapeutics
US01438T1060

Levi & Korsinsky, LLP notifies investors that Michael Alferi, Head of Finance, principal financial officer, and principal accounting officer of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), is named as an individual defendant in a securities class action covering purchases between November 3, 2023 and March 16, 2026. Find out if you can recover l...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 21.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner J...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). Shareholders who purchased shares of ALDX during the class period listed are encoura...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securi...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 20, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inc...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Aldeyra Therapeutics
US01438T1060

LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Sha...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securities...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 19.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 19.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securi...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 18.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securities...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner J...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 16.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securi...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Aldeyra Therapeutics
US01438T1060

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRANEW YORK, April 16, 2026 /PRNewswire/ -- IMPORTANT DATE: May 29, 2026. Investors who purchased Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026 and wish to seek appointment as lead plaintiff must file a motion by this date. Start y...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Aldeyra Therapeutics
US01438T1060

SAN DIEGO, April 15, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as "biotechnology company devoted to discovering...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 15, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inc...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Aldeyra Therapeutics
US01438T1060

Key Dates and Disclosure Events Shareholders Need to KnowNEW YORK, April 15, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP encourages investors who suffered losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) to contact the firm. WHO IS AFFECTED: Those who purchased ALDX securities between November 3, 2023 and March 16, 2026 may be entitled to re...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securi...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securi...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 12.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securi...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 12.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner J...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 11.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securi...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 11.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 10.04.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inc...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 10.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securi...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 10.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-m...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 08.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securit...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 08.04.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 7, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Aldeyra Therapeutics
US01438T1060

Lead Plaintiff Deadline is May 29, 2026NEW YORK, April 7, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP informs investors that a securities fraud class action lawsuit has been filed against Aldeyra Therapeutics, Inc., ("Aldeyra" or the "Company") (NASDAQ: ALDX)   on behalf of investors that bought securities between November 3...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). Shareholders who purchased shares of ALDX during the class period listed are encourag...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"). A class action lawsuit...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 06.04.2026       Aldeyra Therapeutics
US01438T1060

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shar...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 05.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 04.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"). A class action la...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 03.04.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner J...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 03.04.2026       Aldeyra Therapeutics
US01438T1060

LOS ANGELES, April 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shar...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Aldeyra Therapeutics
US01438T1060

SAN DIEGO, April 2, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as "biotechnology company devoted to discovering...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink